BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18209648)

  • 21. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
    Goñi FJ;
    Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%.
    Chan K; Testa M; McCluskey P
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):372-6. PubMed ID: 17803436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers.
    Mungan NK; Wilson TW; Nischal KK; Koren G; Levin AV
    J AAPOS; 2003 Feb; 7(1):69-70. PubMed ID: 12690374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy.
    Lee JS; Kim CY
    Expert Rev Clin Pharmacol; 2022 Aug; 15(8):911-919. PubMed ID: 35951740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anterior uveitis and topical brimonidine: a case report].
    Velasque L; Ducousso F; Pernod L; Vignal R; Deral V
    J Fr Ophtalmol; 2004 Dec; 27(10):1150-2. PubMed ID: 15687926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allergic contact dermatitis caused by topical eye drops.
    Spaeth GL
    Am J Ophthalmol; 2006 Oct; 142(4):706. PubMed ID: 17011880
    [No Abstract]   [Full Text] [Related]  

  • 28. Preclinical safety profile of brimonidine.
    Angelov OV; Wiese AG; Tang-Liu DD; Acheampong AA; Ismail IM; Brar BS
    Eur J Ophthalmol; 1996; 6(1):21-5. PubMed ID: 8744846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is brimonidine ophthalmic a safe therapy for infants?
    Daubert GP
    J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cicatricial ectropion: a complication of topical 5-fluorouracil.
    Nikkhah D; Abood A; Watt D
    J Plast Reconstr Aesthet Surg; 2012 Jan; 65(1):e9-10. PubMed ID: 21872544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of glaucoma with brimonidine (Alphagan 0.2%)].
    Detry-Morel M; Dutrieux C
    J Fr Ophtalmol; 2000 Oct; 23(8):763-8. PubMed ID: 11033496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
    Greenfield DS; Liebmann JM; Ritch R
    J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy.
    Gordon RN; Liebmann JM; Greenfield DS; Lama P; Ritch R
    Eye (Lond); 1998; 12 ( Pt 4)():697-700. PubMed ID: 9850267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial.
    Wilhelm B; Lüdtke H; Wilhelm H;
    Graefes Arch Clin Exp Ophthalmol; 2006 May; 244(5):551-8. PubMed ID: 16151785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitreous concentration of topically applied brimonidine-purite 0.15%.
    Kent AR; King L; Bartholomew LR
    J Ocul Pharmacol Ther; 2006 Aug; 22(4):242-6. PubMed ID: 16910864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alphagan allergy may increase the propensity for multiple eye-drop allergy.
    Osborne SA; Montgomery DM; Morris D; McKay IC
    Eye (Lond); 2005 Feb; 19(2):129-37. PubMed ID: 15254495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iopidine allergy causing lower eyelid ectropion progressing to cicatricial entropion.
    Britt MT; Burnstine MA
    Br J Ophthalmol; 1999 Aug; 83(8):992-3. PubMed ID: 10636681
    [No Abstract]   [Full Text] [Related]  

  • 39. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma.
    Korsch E; Grote A; Seybold M; Soditt V
    Eur J Pediatr; 1999 Aug; 158(8):685. PubMed ID: 10445353
    [No Abstract]   [Full Text] [Related]  

  • 40. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate.
    Becker HI; Walton RC; Diamant JI; Zegans ME
    Arch Ophthalmol; 2004 Jul; 122(7):1063-6. PubMed ID: 15249377
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.